|
1. |
Prof. Divya Juyal |
Repurposing of ethnobotanically claimed toxic phytoconstituents from plants to Uttarakhand region in treatment of metabolic and associated disorders using network pharmacology integrated with experimental studies |
Uttarakhand Council of Science & Technology, Govt. of Uttarakhand |
2024 |
4 |
|
2. |
Prof. Divya Juyal |
Development of personalised 3D printed transdermal patch of Iron supplement for Anaemia using innovative technology |
Uttarakhand Science Education and Research Centre, Govt. of Uttarakhand |
2024 |
1.5 |
|
3. |
Dr. Maneesha Singh |
Assessment of Genetic Diversity, conservation and utilization of Origanum vulgare L under agroforestry system as livelihood for farmers in Uttarakhand, India |
Uttarakhand Council of Biotechnology |
2024 |
4.05 |
|
4. |
Dr. Sulekha Nautiyal |
Epidemiology of ciruclating serotypes of Dengue in a tertiary care hospital and its correlation with laboratory and clinical profile. |
Uttarakhand Council of Biotechnology |
2024 |
4.9 |
|
5. |
Dr. Anjali Chgaudhary |
Implications of sexually transmitted infections with regard to their influence on female infertility, in a tertiary care hospital of North India |
Uttarakhand Council of Biotechnology |
2024 |
4.25 |
|
6. |
Dr.Tanuj Bhatia |
EX6018-4979, Protocol #: ARTEMIS: Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction and angiographic evidence of type I MI |
Novo Nordisk |
2024 |
0.5 |
|
7. |
Dr.Tanuj Bhatia |
BIO89-100-231: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (SHTG) |
Bio89 |
2024 |
0.5 |
|
8. |
Dr.Tanuj Bhatia |
: EX6018-4915: HERMES - Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation |
Novo Nordisk |
2023 |
2 |
|
9. |
Dr.Tanuj Bhatia |
NN9838-4942: REDEFINE 3: The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c.in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease. |
Novo Nordisk |
2023 |
0.5 |
|
10. |
Dr.Tanuj Bhatia |
CKJX839D12303: A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular events (VICTORION-PLAQUE) |
Novartis |
2023 |
2 |
|
11. |
Dr.Tanuj Bhatia |
NN6018-7527: POSEIDON : Prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease and heart failure. Subject: Notification of updated IU to the Institutional Ethics Committee for the review for the above mentioned study |
Novo Nordisk |
2024 |
0.5 |
|
12. |
Dr. Neeti Kumari |
CLOU064A2304; A global, multicenter, randomized, double-blind, double-dummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines. |
Novartis |
2024 |
0.5 |
|
13. |
Dr. Neeti Kumari |
KBS/OMA/01; A Randomized, Multicenter, Double-Blind, 4-Arm, Parallel-Group, Active-Controlled, Phase 3 Study to Compare Efficacy, Safety and Immunogenicity of ADL-018 150 mg and 300 mg with EU-Approved Xolair® 150 mg and 300 mg Administered Through Subcutaneous Route Every 4 Weeks in Patients with Chronic Idiopathic Urticaria (CIU) who Remained Symptomatic Despite Treatment with Approved Doses of H1 Antihistamines. |
COD |
2024 |
0.5 |
|
14. |
Dr. Vivek Ruhela |
: VT-001-0050, Protocol Title: A Phase 3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN). |
Veera Therputic |
2024 |
1 |
|
15. |
Dr. Rohitash Sharma |
CLOU064C12301 “A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib |
Novartis |
2023 |
2 |
|
16. |
Dr. Mohan Dhyani |
RVP-30-001, Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia, Followed by a 52-Week Open-label Extension. |
Reviva |
2022 |
2 |
|
17. |
Dr. Jagdish Rawat |
D9180C00008 - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO). |
AstraZeneca |
2023 |
2 |
|
18. |
Dr. Lokesh Gambhir |
Bio-prospecting fungal endophytes inhabiting medicinal plants for
L-asparaginase production as prophylaxis of acute lymphocytic leukemia |
Uttarakhand Science Education and Research Centre, Govt of Uttarakhand |
2023 |
4.7 |
|
19. |
Dr. Lokesh Gambhir |
Biomining Endophytic Fungi for selective Nrf2:DNA complex inhibitor: A targeted approach to curb breast cancer |
Uttarakhand Council of Biotechnology, Govt. of Uttarakhand |
2023 |
10.2 |
|
20. |
Dr. Girish Chandra |
Establishment of small scale hydroponics facility to increase the yield and nutrient quality of potato (Solanum tuberosum L.) tuber |
Uttarakhand Council of Biotechnology, Govt. of Uttarakhand |
2023 |
4.1 |
|
21. |
Dr Sunil K Sriwas |
Oraganising a Yoga Program (Hybrid Mode) in connection with the celelbration of 100 days countdown of IDY 2023 |
Morarji Desai National Institute of Yoga |
2023 |
2.0 |
|
22. |
Dr. Mohan Dhyani |
RVP-30-001, Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia, Followed by a 52-Week Open-label Extension |
Reviva Pharmaceuticals |
2023 |
0.9 |
|
23. |
Dr. Pankaj Garg |
Hospital Based Cancer Registries in India |
Indian Council for Medical Research |
2022 |
15.0 |
|
24. |
Dr. Lokesh Gambhir |
Biomining endophytic fungi for selective mitogen activated protein kinase phosphatase-1 (MKP-1) inhibitor(s): A targeted approach for cancer therapeutics |
DST-SERB, Govt. of India |
2022 |
30.6 |
|
25. |
Dr. Lokesh Gambhir |
Isolation and characterisation of cyclooxygenase-2 inhibitor from endophytic fungi inhabiting endangered ethnomedicinal plants of high altitude regions of Uttarakhand |
Uttarakhand Council of Biotechnology, Govt of Uttarakhand |
2022 |
12.05 |
|
26. |
Dr. Alka Chaudhary |
Insilico analysis Designing Alzheimer`s disease: A Green Approach |
USERC, Govt of Uttarakhand |
2022 |
2.41 |
|
27. |
Dr. Sunil K Sriwas |
Organising World Philosophy Day 2022 |
Indian Council for Philosophical Research, Ministry of Education, Govt. of India |
2022 |
0.30 |
|
28. |
Dr. Pooja Jain |
Role of Scientific and Technical Terminology in Quality and Innovation Research Education: A Perspective to NEP 2020 |
Commission of Scientific and Technical Terminology, Ministry of Education, Govt. of India |
2022 |
3 |
|
29. |
Prof. Dwarika Prasad Maithani |
Formulation of Bio-primer from some weeds plants of Uttarakhand as bio-corrosion inhibitors |
Uttarakhand Council of Biotechnology, Govt. of Uttarakhand |
2022 |
9.85 |
|
30. |
Dr. Pooja Jain |
Study of the impact of One District ,One Product Scheme of Government of India on Socio -Economic and Business condition of wooden craft workers in Saharanpur (U.P.) |
Mahatma Gandhi National Council of Rural Education, Govt. Of India |
2022 |
3 |
|
31. |
Dr Naini Puri |
TO establish IGF-1 cut off in a Adolescent male population |
Mamta Health Institute of Mother and Child |
2022 |
1 |
|
32. |
Dr. Rohitash Sharma |
CLOU064C12301 “A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib. |
Novartis Research & Development |
2022 |
1 |
|
33. |
Dr Vivek Ruhela |
D3466C00001, Protocol Title: “A Multicentre Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis” |
AstraZeneca |
2022 |
0.5 |
|
34. |
Dr. Neeti Kumari |
CLOU064A2302; A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines. |
Novartis Research & Development |
2022 |
1.5 |
|
35. |
Dr. Tanuj Bhatia |
AROAPOC3-3001, A phase 3 study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome. |
Medpace |
2022 |
0.5 |
|
36. |
Dr.Rohitash Sharma |
CLOU064C12301 “A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib. |
Novartis Research & Development |
2022 |
0.75 |
|
37. |
Dr. Vivek Ruhela |
CLNP023A2301, Protocol Title: “A multi-center, randomized, double-blind, placebo controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients”. |
Novartis Research & Development |
2022 |
0.75 |
|
38. |
Shri Guru Ram Rai University |
Research Project Grants (i) Establishment of catheterization laboratory in cardiology (ii) Establishment of catheterization laboratory in Intervention Radiology (iii) MRI based epidemiological tumor studies and image analysis for developing the AI tool for epidemiological tumor studies and image analysis for developing the AI tool for early detection. (iv) SGRR-STI hub for innovation and Skill Development (v) Establishment of Animal Cell Line Culture facility for identifying the putative chemotherapeutic agent to curb triple negative breast cancer and Hepatocarcinoma |
Shri Guru Mandal Ashram Samiti, Haridwar, Uttarakhand |
2022 |
2100 |
|
39. |
Dr. Yogendra Bahuguna |
Identification and comparison of tissue cultured Zanthoxylum armatum DC (Timur) species with their wild correspondences and development of smart recommender system for cultivation in Uttarakhand Himalayan region |
UCOST, Govt of Uttarakhand |
2021 |
9.218 |
|
40. |
Dr. Jagdish Rawat |
D5982C00007 - Study Title: A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS) |
AstraZeneca |
2021 |
0.75 |
|
41. |
Dr. Jagdish Rawat |
A phase II, Multicentric, Randomised, Double blind, Chronic-dosing, parallel Group, Placebo controlled study to evaluate the efficacy and safety of Two Dose Regimens of MED13506 in participants with Symptomatic Chronic Obstructuive Pulmonary Disease (COPD) with a history of COPD Exacerbations (OBERON) |
Novartis Research & Development |
2021 |
0.75 |
|
42. |
Dr. Tanuj Bhatia |
CTQJ230A12001: Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease. |
Novartis Research & Development |
2021 |
2.23 |
|
43. |
Dr. Tanuj Bhatia |
CTQJ230A12301: A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease. |
Novartis Research & Development |
2021 |
6.51 |
|
44. |
Dr. Vivek Ruhela |
CAIN457Q1230, Protocol Title: “A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy and tolerability of 300mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis”. |
Novartis Research & Development |
2021 |
0.5 |
|
45. |
Dr. Vivek Ruhela |
CLNP023D12201, Protocol Title: “A randomized, treatment open-label, dose-blinded parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathy”. |
Novartis Research & Development |
2021 |
1 |
|
46. |
Dr. Vivek Ruhela |
CLNP023B12301, Protocol Title: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy. |
Novartis Research & Development |
2021 |
0.5 |
|
47. |
Dr. Ashish Kakkar |
“A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy” |
Novartis Research & Development |
2021 |
0.5 |
|
48. |
Dr. Mohan Dhyani |
NW-3509/008/II/2019: “A Phase II, Prospective, Multi-Center, Randomized, 4-Week, Double-Blind, Placebo-Controlled, Multiple-Dose Study, Designed To Determine the Safety, Tolerability, EEG Effects AND Preliminary Efficacy Of Fixed Oral Doses Of 7.5 and 15 mg BID Of EVENAMIDE (NW-3509) in Patients With Chronic Schizophrenia Who Are Symptomatic On Their Current Second-Generation Antipsychotic (Aripiprazole, Clozapine, Quetiapine, Olanzapine, Paliperidone OR Risperidone) Medication” |
CliniRx |
2020 |
0.5 |
|
49. |
Dr. Jagdish Rawat |
CT-007-FLPR-2017 - “A Prospective, Multi-center, Randomized, Assessor-blind, Parallel-group, Comparative Clinical Endpoint Bioequivalence Study to Compare the Efficacy and Safety of Generic Fluticasone Propionate Inhalation Aerosol (pMDI, HFA 134a) (test drug) (of Macleods Pharmaceuticals Ltd) versus the Reference Listed Drug FLOVENT HFA (pMDI) Inhalation Aerosol and Efficacy and Safety of both Test and RLD to a Placebo-control in Treatment of Patients with Bronchial Asthma |
Mecleods |
2020 |
1 |
|
50. |
Dr. Tanuj Bhatia |
CLCZ696G2301 “A multi-center, randomized, double-blind, active-controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk patients following an acute myocardial infarction. |
Novartis Research & Development |
2020 |
5.16 |
|
51. |
Dr. Vivek Ruhela |
DESI.19.001.01, Study entitled, “A Phase 3, Multicenter, Open-label, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet Versus Epoetin Alfa Injection for the Treatment of Anemia in Patients with Chronic Kidney Disease (CKD) on Dialysis. (DREAM-D).” |
Cadila Healthcare |
2020 |
0.5 |
|
52. |
Dr. Priyanka Kashyap |
“A 12 – Week double-blind, Randomized, Multi –Center study comparing the efficacy and safety of once monthly subcutaneous AMG 334 against placebo in adult episodic migraine patients (EMPOwER). |
Novartis Research & Development |
2020 |
8.12 |
|
53. |
Dr. Rohitash Sharma |
CAMG334A2304 “A 12-week phase 3, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of once monthly subcutaneous erenumab 70 mg in adult chronic migraine patients. |
Novartis Research & Development |
2020 |
6.62 |
|
54. |
Dr. Vivek Ruhela |
20150238, Protocol Title: A Multicenter, Multiple-dose, Active-controlled, Double-blind,Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism |
Amgen |
2019 |
2.28 |
|
55. |
Dr. Vivek Ruhela |
DESI.18.001.01 (Sponsor: Cadila Healthcare Ltd); Study entitled, “A Phase 3, Multicenter, Multi-country, Open-label, Randomized, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Desidustat Versus Darbepoetin for the Treatment of Anemia in Patients with Chronic Kidney Disease (CKD) who are not on Dialysis.” |
Cadila Healthcare |
2019 |
0.5 |
|
56. |
Dr. Sangeeta Huidron |
DST-Women Scientist Award |
Department of Science and Technology-SERB, Govt of India |
2019 |
27.55 |
|
57. |
Dr. Rajeev Khushwaha |
Study of Blood lead levels hemoglobin levels and urinary iodine as development indicators in children 12 year residing nearvy areas of Rispana river of Dehradun |
Uttarakhand Science Education & Research Centre, Govt. of Uttarakhand |
2019 |
1.75 |
|
58. |
Dr. Jagdish Rawat |
CP/01/17, Protocol Title: “A Phase IV, Prospective, Open Label, Non-Comparative, Multicenter study With 24 Week of Treatment Period to Assess Safety, Tolerability and efficacy of Pirfenidone 200mg Oral Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF) |
Cipla Ltd. |
2019 |
0.75 |
|
59. |
Dr. Jagdish Rawat |
CQAVM149B2302, Protocol Title: “A multicenter, randomized, 52-week, double-blind, parallel group, activecontrolled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma to standard-of-care asthma therapy in patients with uncontrolled asthma” |
Novartis Research & Development |
2018 |
6.96 |
|
60. |
Dr. Jagdish Rawat |
CQAW039A2317, Protocol Title: “A 12 week, multicentre, randomized, double blind, placebo-controlled study to assess the efficacy and safety of QAW039 When added to standard-of-care asthma therapy in patients with uncontrolled asthma” |
Novartis Research & Development |
2018 |
3.05 |
|
61. |
Dr. Jagdish Rawat |
CQAW039A2315,”A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma” |
Novartis Research & Development |
2018 |
0.64 |
|
62. |
Dr. Pankaj Dixit |
J1P-MC-KFAH(a): An Adaptive Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3471851 (NKTR-358) in Patients with Moderately to Severely Active Ulcerative Colitis. |
Eli Lilly |
2018 |
0.5 |
|
63. |
Dr. Priyanka Kashyap |
D5134C00003, A Randomized, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III study to Investigate the Efficacy and Safety of Ticagrelor and ASA compared with ASA in the prevention of Stroke and Death in patients with Acute Ischaemic Stroke or Transient Ischaemic Attack. |
AstraZeneca |
2018 |
0.5 |
|
64. |
Dr. Priyanka Kashyap |
CT/LACO/EPI/13: Protocol Title: “A Multicenter, Open-Label, Non-Comparative Clinical Trial to Evaluate Safety and Tolerability of Lacosamide Injection in patients with partial Onset Seizyres”. |
Torrent |
2018 |
0.5 |
